About this Session:
Disease impacts all people, so shouldn’t the drug development process be representative of all people? Diversity has historically been overlooked in clinical trial design and implementation, until now. Motivated by the troubling statistics around the pandemic’s impact on racial and ethnic minority groups, life sciences leaders are stepping up to ensure diversity is deeply ingrained into the planning and execution of all clinical trials, leaving bias in the past.